Grundläggande statistik
| CIK | 946840 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Shire Viropharma Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| February 25, 2014 |
ViroPharma announces results of tender offer for its 2.00% Convertible Senior Notes Due 2017 Exhibit (a)(5)(B) ViroPharma announces results of tender offer for its 2.00% Convertible Senior Notes Due 2017 Exton, PA, US — February 25, 2014 — ViroPharma Incorporated today announced the results of its tender offer (the “Convertible Notes Tender Offer”) pursuant to which each holder of the 2.00% Convertible Senior Notes Due 2017 (the “Convertible Notes”) had the right (the “Fundamental Change |
|
| February 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VIROPHARMA INCORPORATED (Name of Filing Person (Issuer)) 2.00% Convertible Senior Notes due 2017 (Title of Class of Securities) 928241AH1 (CUS |
|
| February 14, 2014 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of ViroPharma Incorporated is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2014 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, it |
|
| February 14, 2014 |
VPHM / Shire Viropharma Inc / Palo Alto Investors, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) ViroPharma Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 928241108 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2014 |
VPHM / Shire Viropharma Inc / BAKER FELIX - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2014 |
VPHM / Shire Viropharma Inc / VANGUARD GROUP INC Passive Investment viropharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: ViroPharma Inc Title of Class of Securities: Common Stock CUSIP Number: 928241108 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to desi |
|
| February 10, 2014 |
VPHM / Shire Viropharma Inc / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* VIROPHARMA INC (Name of Issuer) Common Stock (Title of Class of Securities) 928241108 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-21699 ViroPharma Incorporated (Exact name of registrant as specified in |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VIROPHARMA INCORPORATED (Name of Filing Person (Issuer)) 2.00% Convertible Senior Notes due 2017 (Title of Class of Securities) 928241AH1 (CUS |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION VIROPHARMA INCORPORATED * * * EX-3.1 2 dp43315ex0301.htm EXHIBIT 3.1 Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIROPHARMA INCORPORATED * * * FIRST: The name of the corporation is ViroPharma Incorporated (the “Corporation”). SECOND: The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2014 (January 23, 2014) VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorpo |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VIROPHARMA INCORPORATED (Name of Filing Person (Issuer)) 2.00% Convertible Senior Notes due 2017 (Title of Class of Securities) 928241AH1 (CUSIP Number of Class |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
Exhibit (a)(5) ViroPharma announces tender offer for its 2.00% Convertible Senior Notes Due 2017 Exton, PA, US—January 24, 2014—ViroPharma, Inc. today announced that, in connection with the completion of the acquisition of ViroPharma by Shire plc (LSE: SHP, NASDAQ: SHPG), it has commenced a tender offer (the “Convertible Notes Tender Offer”) to repurchase, at the option of each holder, any and all |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share ( |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 7) VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person Filing Statement) Common Stock, $0.002 par value per share (Title of Class of Securities) 928241108 (CUSI |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
AMENDED AND RESTATED BYLAWS VIROPHARMA INCORPORATED * * * * * ARTICLE 1 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF VIROPHARMA INCORPORATED * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Dire |
|
| January 24, 2014 |
Exhibit (a)(1) FUNDAMENTAL CHANGE REPURCHASE RIGHT NOTICE, NOTICE OF RIGHT TO CONVERT, NOTICE OF ENTRY INTO SUPPLEMENTAL INDENTURE AND OFFER TO REPURCHASE TO HOLDERS OF 2. |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 24, 2014 |
EX-99.D.3 2 dp43361exd3.htm EXHIBIT (D)(3) Exhibit (d)(3) SUPPLEMENTAL INDENTURE This Supplemental Indenture (this “Supplemental Indenture”) is dated as of January 24, 2014 between ViroPharma Incorporated, a Delaware corporation (the “Issuer”), and Wilmington Trust Company, a Delaware trust company, as Trustee under the Indenture defined below (the “Trustee”). W I T N E S S E T H WHEREAS, the Issu |
|
| January 24, 2014 |
Shire successfully completes tender offer for ViroPharma EX-99.(A)(5)(XVII) 2 dp43311exa5xvii.htm EXHIBIT (A)(5)(XVII) Exhibit (a)(5)(xvii) Press Release www.shire.com Shire successfully completes tender offer for ViroPharma Dublin, Ireland – January 24, 2014 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of ViroPharma (NASDAQ: VPHM). The tender offer expired at midnight, Ne |
|
| January 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-34129 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-60951 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38248 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-38256 POST-EFF |
|
| January 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 6) VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person Filing Statement) Common Stock, $0.002 par value per share (Title of Class of Securities) 928241108 (CUSI |
|
| January 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share ( |
|
| January 15, 2014 |
Shire waives OFT condition relating to the acquisition of ViroPharma Inc. EX-99.A5XV 2 dp43155sctota-exa5xv.htm EXHIBIT (A)(5)(XV) Exhibit (a)(5)(xv) Press Release www.shire.com Shire waives OFT condition relating to the acquisition of ViroPharma Inc. Dublin, Ireland – January 15, 2014 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has waived the Office of Fair Trading (OFT) approval condition to the announced tender offer for all of the outstanding shares of Vi |
|
| January 15, 2014 |
Exhibit (a)(5)(xvi) 725 Chesterbrook Blvd. Wayne Pennsylvania 19087 United States www.shire.com January 15, 2014 Dear ViroPharma Colleagues, When we first met with you in November following the initial merger announcement we committed to communicating information to you when we had it available. In December, we provided a brief update on how we were progressing through integration planning. Today |
|
| January 10, 2014 |
SC 14D9/A 1 a13-261005sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person Filing Statement) Common Stock, $0.002 par value per share (T |
|
| January 10, 2014 |
Shire extends tender offer for ViroPharma Exhibit (a)(5)(xiv) Press Release www.shire.com Shire extends tender offer for ViroPharma Dublin, Ireland – January 10, 2014 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has extended the expiration of its previously announced tender offer by a wholly owned subsidiary of Shire for all of the outstanding common shares of ViroPharma Incorporated (NASDAQ: VPHM) until midnight, New York City |
|
| January 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share ( |
|
| December 30, 2013 |
Exhibit (a)(13) Colleagues, As we continue our efforts to keep you as informed as possible with details about our merger with Shire Pharmaceuticals, we wanted to provide additional clarity and information on a few subjects that have generated many questions recently, namely treatment of equity awards and other matters relating to bonuses and compensation. |
|
| December 30, 2013 |
Exhibit (a)(14) Colleagues, As we continue our efforts to keep you as informed as possible with details about our merger with Shire Pharmaceuticals, we wanted to provide additional clarity and information on a few subjects that have generated many questions recently, namely treatment of equity awards and other matters relating to bonuses and compensation. |
|
| December 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person Filing Statement) Common Stock, $0.002 par value per share (Title of Class of Securities) 928241108 (CUSI |
|
| December 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person Filing Statement) Common Stock, $0.002 par value per share (Title of Class of Securities) 928241108 (CUSI |
|
| December 27, 2013 |
Shire extends tender offer for ViroPharma Exhibit (a)(5)(xiii) Press Release www.shire.com Shire extends tender offer for ViroPharma Dublin, Ireland – December 27, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has extended the expiration of its previously announced tender offer by a wholly owned subsidiary of Shire for all of the outstanding common shares of ViroPharma (NASDAQ: VPHM) until midnight, New York City time, on Th |
|
| December 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share ( |
|
| December 24, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share ( |
|
| December 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share ( |
|
| December 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person Filing Statement) Common Stock, $0.002 par value per share (Title of Class of Securities) 928241108 (CUSI |
|
| December 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share ( |
|
| December 11, 2013 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit (a)(5)(x) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE BRIAN COHEN, on Behalf of Himself and All Others Similarly Situated, Plaintiff, v. |
|
| December 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person Filing Statement) Common Stock, $0.002 par value per share (Title of Class of Securities) 928241108 (CUSI |
|
| December 11, 2013 |
Hart-Scott-Rodino Waiting Period Expires for Shire’s Acquisition of ViroPharma Exhibit (a)(5)(xi) Press Release www.shire.com Hart-Scott-Rodino Waiting Period Expires for Shire’s Acquisition of ViroPharma December 11, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) relating to its previously announced tender offer by a wholly owned subsidiary of Shire for all outstanding shares o |
|
| November 25, 2013 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ViroPharma Incorporated at $50. |
|
| November 25, 2013 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of ViroPharma Incorporated at $50. |
|
| November 25, 2013 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 25, 2013 |
EX-99.(A)(5)(VIII) 9 a2217491zex-99a5viii.htm EX-99.(A)(5)(VIII) Exhibit (a)(5)(viii) EFiled: Nov 20 2013 06:33PM EST Transaction ID 54592103 Case No. 9108- IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MARY MANLEY, individually and on behalf of all others similarly situated, Plaintiff, v. VIROPHARMA INCORPORATED, VINCENT J. MILANO, PAUL A. BROOKE, WILLIAM D. CLAYPOOL, MICHAEL R. DOUGHERTY, RO |
|
| November 25, 2013 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 25, 2013 |
Exhibit (d)(2) CONFIDENTIAL June 20, 2013 Shire Pharmaceutical Holdings Ireland Limited 5 Riverwalk Citywest Business Campus Dublin 24, Ireland Attn: David Colpman Re: Confidentiality Agreement Ladies and Gentlemen: Shire Pharmaceutical Holdings Ireland Limited, a company incorporated in Ireland (“SPHIL”), has expressed interest in exploring a possible transaction with, acquisition of or business combination (directly or through one or more of its affiliates) with ViroPharma Incorporated, a Delaware corporation (together with its subsidiaries, the “Company”), and/or one of its affiliates (any of the foregoing, a “Transaction”). |
|
| November 25, 2013 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit (a)(5)(ix) EFiled: Nov 21 2013 06:28PM EST Transaction ID 54597778 Case No. |
|
| November 25, 2013 |
730 Stockton Drive Exton, PA 19341 Phone (610) 458-7300 Fax (610) 458-7380 QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(7) 730 Stockton Drive Exton, PA 19341 Phone (610) 458-7300 Fax (610) 458-7380 November 25, 2013 Dear ViroPharma Stockholders: We are pleased to report that ViroPharma Incorporated (the "Company") has entered into an Agreement and Plan of Merger, dated as of November 11, 2013 (the "Merger Agreement"), with Shire Pharmaceutical Holdings Ireland Limited ("SPHIL"), Venus Newco, Inc. |
|
| November 25, 2013 |
Exhibit (a)(5)(vii) EFiled: Nov 19 2013 03:17PM EST Transaction ID 54581935 Case No. |
|
| November 25, 2013 |
Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ViroPharma Incorporated at $50. |
|
| November 25, 2013 |
Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| November 25, 2013 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of ViroPharma Incorporated at $50. |
|
| November 25, 2013 |
EX-99.(A)(1)(IV) 5 a2217491zex-99a1iv.htm EX-99.(A)(1)(IV) QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ViroPharma Incorporated at $50.00 Net Per Share by Venus Newco, Inc. a wholly owned subsidiary of Shire Pharmaceutical Holdings Ireland Limited THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 6 |
|
| November 14, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organiza |
|
| November 14, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person(s) Filing Statement) Common Stock, $0.002 par value per share (Title of Class of Securities) 928241108 (CUSIP Number of Class of Securiti |
|
| November 14, 2013 |
Exhibit 99.1 730 Stockton Drive Exton, Pennsylvania 19341 ViroPharma Incorporated November 14, 2013 To: Holders of ViroPharma Incorporated 2.00% Convertible Senior Notes due 2017 and Wilmington Trust Company, as the Trustee and Paying Agent under the Indenture Rodney Square North 1100 North Market Street Wilmington, Delaware 19890 Corporate Trust Office Attention: Corporate Client Services (ViroPh |
|
| November 12, 2013 |
Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER dated as of November 11, 2013, among SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED, VENUS NEWCO, INC., VIROPHARMA INCORPORATED and SHIRE PLC (solely for the purposes set forth in Section 10.16) TABLE OF CONTENTS Page ARTICLE I THE OFFER Section 1.1 The Offer 2 Section 1.2 Company Actions 4 Section 1.3 Directors 6 ARTICLE II THE MERGER Section |
|
| November 12, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 VIROPHARMA INCORPORATED (Name of Subject Company) VIROPHARMA INCORPORATED (Name of Person(s) Filing Statement) Common Stock, $0.002 par value per share (Title of Class of Securities) 928241108 (CUSIP Number of Class of Securiti |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share (Title of Class of |
|
| November 12, 2013 |
Exhibit 10.1 EXECUTION VERSION SHIRE PLC as the Company MORGAN STANLEY BANK INTERNATIONAL LIMITED as mandated lead arranger and bookrunner with MORGAN STANLEY BANK INTERNATIONAL LIMITED as Agent US$ 2,600,000,000 TERM FACILITIES AGREEMENT DATED 11 NOVEMBER 2013 Slaughter and May One Bunhill Row London EC1Y 8YY (REL/APXK) 516285245 CONTENTS Clause Page 1. Definitions and interpretation 1 2. The Fac |
|
| November 12, 2013 |
Exhibit 99.1 Press Release www.shire.com Shire to acquire ViroPharma in strategic move to strengthen rare disease portfolio; will augment already strong growth prospects Earnings accretive, revenue growth-enhancing acquisition Dublin, Ireland and Exton, PA, US – November 11, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG) and ViroPharma Incorporated (NASDAQ: VPHM) today announce that their Boards of Dir |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2013 (November 11, 2013) SHIRE PLC (Exact name of registrant as specified in its charter) Jersey, Channel Islands 0-29630 98-0601486 (State or other jurisdiction of incor |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share (Title of Class of |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2013 (November 11, 2013) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Exact name of registrant as specified in its charter) Jersey, Channel |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share (Title of Class of |
|
| November 12, 2013 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2013 |
Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER dated as of November 11, 2013, among SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED, VENUS NEWCO, INC., VIROPHARMA INCORPORATED and SHIRE PLC (solely for the purposes set forth in Section 10.16) TABLE OF CONTENTS Page ARTICLE I THE OFFER Section 1.1 The Offer 2 Section 1.2 Company Actions 4 Section 1.3 Directors 6 ARTICLE II THE MERGER Section |
|
| November 12, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organiza |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share (Title of Class of |
|
| November 12, 2013 |
Exhibit 99.1 Press Release www.shire.com Shire to acquire ViroPharma in strategic move to strengthen rare disease portfolio; will augment already strong growth prospects Earnings accretive, revenue growth-enhancing acquisition Dublin, Ireland and Exton, PA, US — November 11, 2013 — Shire plc (LSE: SHP, NASDAQ: SHPG) and ViroPharma Incorporated (NASDAQ: VPHM) today announce that their Boards of Dir |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 VIROPHARMA INCORPORATED (Name of Subject Company (Issuer)) VENUS NEWCO, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.002 Per Share (Title of Class of |
|
| October 31, 2013 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody, Jr. Director, Investor Relations Phone (610) 321-6290 Michelle Larkin (media) Manager, PR & Advocacy Phone (610) 304-5842 VIROPHARMA Incorporated Reports Third Quarter 2013 Financial Results - Cinryze® (C1 Esterase Inhibitor [Human]) North American Ne |
|
| October 31, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-21699 VIROPHARMA INCORPORATED (Exact Nam |
|
| October 31, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a13-2297628k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 31, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of |
|
| September 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 29, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizati |
|
| August 12, 2013 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 12, 2013 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of ViroPharma Incorporated is being filed with the Securities and Exchange Commission on behalf of each of them. August 12, 2013 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its |
|
| August 1, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 1, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdiction of Incorporation or Organization) 0-021699 (Commiss |
|
| August 1, 2013 |
Exhibit 99.2 VIROPHARMA INCORPORATED Contacts: Michelle Larkin Manager, PR and Advocacy Phone: 610-321-2886 Robert Doody Director, Investor Relations Phone: 610-321-6288 VIROPHARMA PROVIDES UPDATE ON PHASE 2 CLINICAL EVALUATION OF SUBCUTANEOUS CINRYZE® (C1 ESTERASE INHIBITOR [human] WITH RECOMBINANT HUMAN HYALURONIDASE (rHuPH20) Exton, PA, August 1, 2013 — ViroPharma Incorporated (NASDAQ: VPHM) to |
|
| August 1, 2013 |
VIROPHARMA INCORPORATED ANNUAL INCENTIVE PLAN Exhibit 10.1 VIROPHARMA INCORPORATED ANNUAL INCENTIVE PLAN 1. Purpose The purpose of the ViroPharma Incorporated Annual Incentive Plan (the “Plan”) is to enhance the ability of ViroPharma Incorporated (the “Company”) to attract, reward and retain employees, to strengthen employee commitment to the Company’s success and to align employee interests with those of the Company’s stockholders by providi |
|
| August 1, 2013 |
VIROPHARMA Announces Second Quarter 2013 Financial Results Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody Jr. Director, Investor Relations Phone (610) 321-6290 Michelle Larkin (media) Manager, PR & Advocacy Phone (610) 304-5842 VIROPHARMA Announces Second Quarter 2013 Financial Results EXTON, PA, August 1, 2013 — VIROPHARMA INCORPORATED (Nasdaq: VPHM) toda |
|
| August 1, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-21699 VIROPHARMA INCORPORATED (Exact Name of |
|
| June 27, 2013 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Michelle Larkin Manager, PR and Advocacy Phone: 610-321-2886 Robert Doody Director, Investor Relations Phone: 610-321-6288 VIROPHARMA PROVIDES UPDATE FROM ONGOING PHASE 2 STUDIES OF MARIBAVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTIONS Exton, PA, June 27, 2013 — ViroPharma Incorporated (Nasdaq: VPHM) today announced updated data from the two ong |
|
| June 27, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 27, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organization |
|
| May 24, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 23, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdiction of Incorporation or Organization) 0-021699 (Commissio |
|
| May 1, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-21699 VIROPHARMA INCORPORATED (Exact Name of |
|
| May 1, 2013 |
AMENDMENT NO. 3 Dated as of March 13, 2013 CREDIT AGREEMENT Dated as of September 9, 2011 Exhibit 10.1 AMENDMENT NO. 3 Dated as of March 13, 2013 to CREDIT AGREEMENT Dated as of September 9, 2011 THIS AMENDMENT NO. 3 (this ?Amendment?) is made as of March 13, 2013 by and among ViroPharma Incorporated, a Delaware corporation (the ?Borrower?), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the ?Administrative Agent? |
|
| May 1, 2013 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody Jr. Director, Investor Relations Phone (610) 321-6290 Michelle Larkin (media) Manager, PR & Advocacy Phone (610) 304-5842 VIROPHARMA Announces First Quarter 2013 Financial Results - Quarterly Global Cinryze® (C1 esterase inhibitor [human]) Net Sales Gr |
|
| May 1, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 1, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdiction of Incorporation or Organization) 0-021699 (Commission |
|
| April 22, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 22, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdiction of Incorporation or Organization) 0-021699 (Commiss |
|
| April 22, 2013 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Michelle M. Larkin (media) Manager, PR & Advocacy Phone (610) 321- 2886 [email protected] Robert A. Doody Jr. (investors) Director, Investor Relations Phone (610) 321-6290 R. Clayton Fletcher Vice President, Business Development Phone (610) 321-6789 TREATMENT WITH VP20621 (NON-TOXIGENIC Clostridium difficile; NTCD) IN A PHASE 2 STUDY RESU |
|
| April 19, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 19, 2013 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 13, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| March 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 1, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of (Commission File Number) (I.R |
|
| February 27, 2013 |
Exhibit 10.32 VIROPHARMA INCORPORATED 2000 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated effective January 1, 2013) 1. Purpose. The ViroPharma Incorporated 2000 Employee Stock Purchase Plan (the “Plan”) is intended to encourage and facilitate the purchase of Shares of the Common Stock of ViroPharma Incorporated (the “Company”) by employees of a Participating Company, thereby providing empl |
|
| February 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 27, 2013 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody Jr. Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (media) Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results - Company Delivers Record Full Year Wo |
|
| February 27, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 27, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organiza |
|
| February 27, 2013 |
FIRST AMENDMENT TO MANUFACTURING AND DISTRIBUTION AGREEMENT (EUROPE AND ROW) Exhibit 10.63 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. FIRST AMENDMENT TO MANUFACTURING AND DISTRIBUTION AGREEMENT (EUROPE AND ROW) ViroPharma |
|
| February 27, 2013 |
Exhibit 21 SUBSIDIARIES OF THE COMPANY Entity Name of State/Country of Incorporation ViroPharma Biologics, Inc. |
|
| February 27, 2013 |
Exhibit 10.62 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as ?***?. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. DCI Management Group, LLC 1019 Fort Salonga Road, Suite 109, Northport, NY 11768 Phone: |
|
| February 14, 2013 |
SC 13G/A 1 viropharm13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) ViroPharma Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 928241108 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 11, 2013 |
DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VIROPHARMA INC (Name of Issuer) Common Stock (Title of Class of Securities) 928241108 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: ViroPharma Inc Title of Class of Securities: Common Stock CUSIP Number: 928241108 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: (X) R |
|
| February 1, 2013 |
BAKER BROS. ADVISORS LP - SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 18, 2013 |
ViroPharma Incorporated 730 Stockton Drive Exton, PA 19341 Tel: (610) 458-7300 Fax: (610) 458-7380 January 18, 2013 VIA EDGAR AND FAX Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D. |
|
| January 9, 2013 |
2013 JP Morgan Healthcare Conference ViroPharma Incorporated January 8, 2013 EX-99.1 2 a13-23161ex99d1.htm EX-99.1 Exhibit 99.1 2013 JP Morgan Healthcare Conference ViroPharma Incorporated January 8, 2013 2 This presentation contains certain forward-looking statements, including statements regarding our financial guidance for 2013 and 2015, peak year sales estimates for our commercial products, our projected financial condition, the rate of future growth and the developmen |
|
| January 9, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 8, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizati |
|
| January 7, 2013 |
VIROPHARMA PROVIDES 2013 OUTLOOK - Provides 2013 Annual Net Sales Guidance of Up to $475 Million - Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Will Roberts (Media) Corporate Communications Phone (610) 321-6288 Robert A. Doody Jr. (Investors) Investor Relations Phone (610) 321-6290 VIROPHARMA PROVIDES 2013 OUTLOOK - Provides 2013 Annual Net Sales Guidance of Up to $475 Million - Exton, PA, January 7, 2013 — ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president |
|
| January 7, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 7, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizati |
|
| January 4, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 3, 2013 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of (Commission File Number) (I |
|
| December 14, 2012 |
ViroPharma Incorporated 730 Stockton Drive Exton, PA 19341 Tel: (610) 458-7300 Fax: (610) 458-7380 December 14, 2012 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D. |
|
| December 12, 2012 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 6, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdiction of Incorporation or Organization) 0-021699 (Commi |
|
| October 25, 2012 |
VIROPHARMA INCORPORATED AMENDED AND RESTATED 2005 EQUITY INCENTIVE PLAN Exhibit 10.3 VIROPHARMA INCORPORATED AMENDED AND RESTATED 2005 EQUITY INCENTIVE PLAN The purposes of the Plan are to: (a) further the growth and success of ViroPharma Incorporated (the “Company”) and its Subsidiaries by enabling selected employees, directors, consultants and advisors of the Company and any Subsidiaries to acquire shares of common stock of the Company, thereby increasing their pers |
|
| October 25, 2012 |
2012 STRATEGIC SUPPLY AGREEMENT Exhibit 10.2 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as ?***?. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 2012 STRATEGIC SUPPLY AGREEMENT This Strategic Supply Agreement (this ?Agreement?) is en |
|
| October 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-21699 VIROPHARMA INCORPORATED (Exact Nam |
|
| October 25, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 25, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or |
|
| October 25, 2012 |
Press Release Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody, Jr. Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports Third Quarter 2012 Financial Results - Quarter Highlighted by Record U.S. Cinryze® (C1 esterase inhibit |
|
| October 25, 2012 |
EX-10.1 2 d414649dex101.htm AMENDED AND RESTATED LEASE Exhibit 10.1 AMENDED AND RESTATED LEASE FOR COMBINATION OFFICE/WAREHOUSE AT EAGLEVIEW CORPORATE CENTER 730 STOCKTON DRIVE LANDLORD: 730 STOCKTON DRIVE ASSOCIATES, L.P. and THE HANKIN GROUP TENANT: VIROPHARMA INCORPORATED TABLE OF CONTENTS Page 1. LEASED SPACE AND PURPOSE 2 2. TERM 2 3. RENT 4 4. ADDITIONAL RENT 8 5. NEGATIVE COVENANTS OF TENAN |
|
| October 22, 2012 |
VIROPHARMA INCORPORATED AMENDED AND RESTATED 2005 EQUITY INCENTIVE PLAN Exhibit 10.1 VIROPHARMA INCORPORATED AMENDED AND RESTATED 2005 EQUITY INCENTIVE PLAN The purposes of the Plan are to: (a) further the growth and success of ViroPharma Incorporated (the “Company”) and its Subsidiaries by enabling selected employees, directors, consultants and advisors of the Company and any Subsidiaries to acquire shares of common stock of the Company, thereby increasing their pers |
|
| October 22, 2012 |
- FORM S-8 - VIROPHARMA INCORPORATED Form S-8 - Viropharma Incorporated As filed with the Securities and Exchange Commission on October 22, 2012 Registration No. |
|
| October 3, 2012 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 1, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizati |
|
| September 25, 2012 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 24, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organiz |
|
| September 21, 2012 |
Slide Presentation Exhibit 99.1 Broadening Horizons 2012 ViroPharma Incorporated Investor Day September 21, 2012 Introduction Vincent Milano Chief Executive Officer 2 This presentation contains certain forward-looking statements, including statements regarding our financial guidance for 2012 and beyond, our projected financial condition, the rate of future growth and the development and commercial |
|
| September 21, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 21, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation o |
|
| September 21, 2012 |
Press Release Exhibit 99.2 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 Shannon Sanders (Media) Manager, PR & Advocacy Phone (610) 321-2886 HALOZYME Contact: Anne Erickson Executive Director, Investor Relations Phone (858) 704-8264 VIROPHARMA AND HALOZYME PROVIDE UPDATE ON CLINICAL DEVELOPMENT OF SUBCUTANEOUS CINRYZE® (C1 ESTERASE IN |
|
| August 31, 2012 |
Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 29, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or O |
|
| August 22, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 20, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or O |
|
| August 9, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 9, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Or |
|
| August 9, 2012 |
EX-10.1 2 d367104dex101.htm AMENDED AGREEMENT FOR THE PURCHASE AND SALE OF BLOOD PLASMA Exhibit 10.1 DCI Management Group, LLC 1019 Fort Salonga Road, Suite 109, Northport, NY 11768 Phone: 631-757-8401 Fax: 631-757-8364 AMENDMENT No. 3 May 1, 2012 ViroPharma Biologics, Inc. 730 Stockton Drive Exton, PA 19341 Re: Third Amendment to that certain Agreement for the Purchase and Sale of Blood Plasma (t |
|
| August 9, 2012 |
AMENDMENT NO. 4 TO DISTRIBUTION AND SUPPLY AGREEMENT Exhibit 10.6 AMENDMENT NO. 4 TO DISTRIBUTION AND SUPPLY AGREEMENT This Amendment No. 4 to Distribution and Supply Agreement (this ?Amendment?) is made as of November 30, 2011, by and among ViroPharma Incorporated, a Delaware corporation (hereinafter referred to as ?Manufacturer?), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as ?Distributor?). Manufacturer and Distri |
|
| August 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-21699 VIROPHARMA INCORPORATED (Exact Name of |
|
| August 9, 2012 |
AMENDMENT NO. 3 TO DISTRIBUTION AND SUPPLY AGREEMENT Amendment No. 3 to Distribution and Supply Agreement Exhibit 10.5 AMENDMENT NO. 3 TO DISTRIBUTION AND SUPPLY AGREEMENT This Amendment No. 3 to Distribution and Supply Agreement (this “Amendment”) is made as of November 30, 2010, by and among ViroPharma Incorporated, a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter r |
|
| August 9, 2012 |
Press Release Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody, Jr. Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (media) Associate Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports Second Quarter 2012 Financial Results - Increases 2012 U.S. Cinryze® (C1 es |
|
| August 9, 2012 |
Exhibit 10.2 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DISTRIBUTION AND SUPPLY AGREEMENT by and between ViroPharma Incorporated and Prasco, LLC dated November 30, 2007 CONFIDENTIAL TREATMENT HAS BEEN REQUE |
|
| August 9, 2012 |
AMENDMENT NO. 2 TO DISTRIBUTION AND SUPPLY AGREEMENT Amendment No. 2 to Distribution and Supply Agreement Exhibit 10.4 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 2 TO DISTRIBUTION AND SUPPLY AGREEMENT ViroPharma Incorporated, a Delaware corporat |
|
| August 9, 2012 |
AMENDMENT NO. 1 TO DISTRIBUTION AND SUPPLY AGREEMENT Amendment No.1 to Distribution and Supply Agreement Exhibit 10.3 AMENDMENT NO. 1 TO DISTRIBUTION AND SUPPLY AGREEMENT This Amendment No. 1 to Distribution and Supply Agreement (this “Amendment”) is made as of June 10, 2008, by and among ViroPharma Incorporated, a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referr |
|
| August 6, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 6, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Or |
|
| August 6, 2012 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Jr. (Investors) Investor Relations Phone (610) 321-6290 VIROPHARMA RECEIVES FDA APPROVAL OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) INDUSTRIAL SCALE MANUFACTURING - Financial Results expected to be released on Thursday, August 9th at 7:30 AM ET - EXTON, Pa., August 6, 2012 — ViroPharma Incorporated (Nasdaq: VPHM) today announced the U |
|
| August 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) x Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2011 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-21699 VI |
|
| August 2, 2012 |
Development and Option Agreement Exhibit 10.62 EXECUTION COPY CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DEVELOPMENT AND OPTION AGREEMENT Dated as of December 22, 2011 by and between VIROPHARMA INCORPORATED |
|
| August 1, 2012 |
Financial Statements and Exhibits, Other Events 8-K 1 d389870d8k.htm VIROPHARMA INCORPORATED - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 1, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdic |
|
| August 1, 2012 |
Press Release Exhibit 99.1 ViroPharma Provides Update on Phase 2 Clinical Evaluation of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) Exton, PA, August 1, 2012 — ViroPharma Incorporated (NASDAQ: VPHM) today announced that ViroPharma and Halozyme Therapeutics were notified by the Center for Biologics Evaluation and Research (CBER) division of t |
|
| June 22, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 20, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Org |
|
| May 23, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 21, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Orga |
|
| May 18, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 18, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Orga |
|
| May 9, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 1, 2012 |
VIROPHARMA Incorporated Reports First Quarter 2012 Financial Press Release Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody, Jr. Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (media) Associate Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports First Quarter 2012 Financial Results EXTON, PA, May 1, |
|
| May 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 1, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organ |
|
| May 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-21699 VIROPHARMA INCORPORATED (Exact Name of Registrant as Spe |
|
| May 1, 2012 |
Amendment to the Intermediate Supply Agreement of 1 June 2009 Exhibit 10.1 [*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ****, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] Amendment to the Intermediate Supply Agreement of 1 June 2009 This Amendment to the Intermediate Supply Agreement (this “Amendment”), dated as of |
|
| April 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 23, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| April 13, 2012 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 13, 2012 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 10, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| April 10, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 9, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdiction of Incorporation or Organization) 0-021699 |
|
| April 10, 2012 |
Press Release Exhibit 99.1 VIROPHARMA INCORPORATED Contact: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 VIROPHARMA PROVIDES UPDATE ON STATUS OF CITIZEN PETITION REGARDING BIOEQUIVALENCE AND EXCLUSIVITY FOR VANCOCIN® (VANCOMYCIN HYDROCHLORIDE, USP) CAPSULES Exton, PA, April 10, 2012 — ViroPharma Incorporated (Nasdaq: VPHM) today announced the U.S. Food and Drug Admin |
|
| March 2, 2012 |
Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 28, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or |
|
| February 28, 2012 |
Exhibit 10.61 Execution Copy [*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ****, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] Share Purchase Agreement RELATING TO THE SALE AND PURCHASE OF ALL SHARES IN DuoCort Pharma AB BETWEEN DuoCort AB (as the Seller) |
|
| February 28, 2012 |
EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT Exhibit 10.58 [*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ****, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT THIS EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT (the ?Agreement?) is made as of Jun |
|
| February 28, 2012 |
Exhibit 21 SUBSIDIARIES OF THE COMPANY Entity Name of State/Country of Incorporation ViroPharma Biologics, Inc. |
|
| February 28, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 28, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or |
|
| February 28, 2012 |
PRESS RELEASE Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody Jr. Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (media) Associate Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results – Co |
|
| February 28, 2012 |
Exhibit 10.59 AMENDMENT NO. 1 TO EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT BETWEEN GENZYME CORPORATION AND VIROPHARMA INCORPORATED This Amendment No. 1 (the ?Amendment?) to the Exclusive Clinical Study and Data License Agreement dated June 12, 2009 (the ?Agreement?) by and between Genzyme Corporation (?Genzyme?) and ViroPharma Incorporated (?ViroPharma?), is effective as of October 22, 2 |
|
| February 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2011 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-21 |
|
| February 28, 2012 |
Exhibit 10.60 [*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ****, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] AMENDMENT NO. 2 TO EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT BETWEEN GENZYME CORPORATION AND VIROPHARMA INCORPORATED This Amendment No |
|
| February 28, 2012 |
Exhibit 10.62 EXECUTION COPY [*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ****, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] DEVELOPMENT AND OPTION AGREEMENT Dated as of December 22, 2011 by and between VIROPHARMA INCORPORATED and MERITAGE PHARMA, INC. [ |
|
| February 14, 2012 |
DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VIROPHARMA INC (Name of Issuer) Common Stock (Title of Class of Securities) 928241108 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 14, 2012 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2012 |
Palo Alto Investors LP - VIROPHARMA INCORPORATED - SCH 13G AMENDMENT NO. 2 CUSIP No. 928241108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ViroPharma Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 928241108 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 10, 2012 |
viropharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.:0 )* Name of issuer: Viropharma Inc Title of Class of Securities: Common Stock CUSIP Number: 928241108 Date of Event Which Requires Filing of this Statement: December 31, 2011 Check the appropriate box to desig |
|
| February 7, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 6, 2012 ViroPharma Incorporated (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or |
|
| February 7, 2012 |
Press Release Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Kristina M. Broadbelt (Media) Associate Director, PR & Advocacy Phone (610) 321-2358 Robert A. Doody Jr. (Investors) Assistant Director, Investor Relations Phone (610) 321-6290 VIROPHARMA PROVIDES UPDATE ON INDUSTRIAL SCALE SUPPLEMENT FOR CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) EXTON, Pa., February 7, 2012 — ViroPharma Incorporated (Nas |
|
| January 6, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 5, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or O |
|
| January 5, 2012 |
VIROPHARMA PROVIDES 2012 OUTLOOK - Provides 2012 Annual Net Sales Guidance of Up to $660 Million - Press Release Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Kristina M. Broadbelt (Media) PR & Advocacy Phone (610) 321-2358 Robert A. Doody Jr. (Investors) Investor Relations Phone (610) 321-6290 VIROPHARMA PROVIDES 2012 OUTLOOK - Provides 2012 Annual Net Sales Guidance of Up to $660 Million - Exton, PA, January 5, 2012 — ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano |
|
| January 5, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 5, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or O |
|
| January 4, 2012 |
VIROPHARMA ANNOUNCES APPOINTMENT OF JULIE H. MCHUGH TO BOARD OF DIRECTORS Press Release Exhibit 99.1 Contacts: Investors Robert A. Doody Assistant Director, IR Phone (610) 321-6290 Media Kristina Broadbelt Assistant Director, Global PR & Advocacy Phone (610) 321- 2358 VIROPHARMA ANNOUNCES APPOINTMENT OF JULIE H. MCHUGH TO BOARD OF DIRECTORS Exton, PA, January 3, 2012 — ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Julie H. McHugh to its board |
|
| January 4, 2012 |
ViroPharma supplement to its citizen petition regarding Vancocin Exhibit 99.2 December 22, 2011 Submitted Electronically Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 730 Stockton Drive Exton, PA 19341 Phone (610) 321-6202 Fax (610) 458-7380 RE: Docket Nos. FDA-2006-P-0007 (formerly 2006P-0124) & FDA-2008-D-0626 Implications o |
|
| January 4, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 3, 2012 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or O |
|
| December 23, 2011 |
ViroPharma Incorporated - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 23, 2011 |
Press Release Exhibit 99.1 VIROPHARMA INCORPORATED contacts: William C. Roberts. Vice President, Corporate Communications Phone (610) 321-6288 Kristina M. Broadbelt (for media) Associate Director, PR & Advocacy Phone (610) 321- 2358 MERITAGE PHARMA contact: Adam K. Simpson Chief Business Officer (858) 436-1634 VIROPHARMA PURCHASES EXCLUSIVE OPTION TO ACQUIRE MERITAGE PHARMA - Option Creates Opport |
|
| December 14, 2011 |
Viropharma Inc-Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 14, 2011 |
Press Release Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: William C. Roberts Vice President, Corporate Communications Phone (610) 321-6288 Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 VIROPHARMA ANNOUNCES APPROVAL OF MODERNIZED LABELING FOR VANCOCIN® (VANCOMYCIN HYDROCHLORIDE, USP) CAPSULES – Modernized Label Provides Safety and Efficacy Data Based on Clinical Stu |
|
| December 6, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Kristina M. Broadbelt (for media) Associate Director, PR & Advocacy Phone (610) 321- 2358 Robert A. Doody Jr. Assistant Director, Investor Relations Phone (610) 321-6290 HALOZYME Contact: Kurt Gustafson Chief Financial Officer Phone (858) 704-8272 VIROPHARMA AND HALOZYME THERAPEUTICS ANNOUNCE POSITIVE DATA FROM INITIAL PHASE 2 ASSESSMENT OF SUBCUTANEO |
|
| December 6, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 6, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizat |
|
| November 15, 2011 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 15, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organiza |
|
| November 15, 2011 |
Exhibit 99.1 Robert A. Doody Jr. (VPHM) Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (VPHM?for media) Associate Director, PR & Advocacy Phone (610) 321? 2358 VIROPHARMA COMPLETES ACQUISITION OF DUOCORT PHARMA AB - Completion Follows European Marketing Authorization and Confirmation of Orphan Drug Designation for Plenadren? (Hydrocortisone, Modified Release Tabl |
|
| November 7, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 7, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizat |
|
| October 27, 2011 |
Robert A. Doody Jr. (VPHM) Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (VPHM - for media) Associate Director, PR & Advocacy Phone (610) 321-2358 Jacob Kaluski (DuoCort Pharma AB) Chairman of the Board of Directors +46 70 356 56 65 Maria Forss (DuoCort Pharma AB) Chief Executive Officer +46 70 967 00 07 VIROPHARMA TO ACQUIRE DUOCORT PHARMA AB, ADDING IMPORTANT |
|
| October 27, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 26, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizat |
|
| October 27, 2011 |
Exhibit 10.1 EXECUTION COPY CREDIT AGREEMENT dated as of September 9, 2011 among VIROPHARMA INCORPORATED, as Borrower The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent and BMO HARRIS FINANCING INC., TD BANK, N.A. and MORGAN STANLEY BANK, N.A. as Co-Syndication Agents J.P. MORGAN SECURITIES LLC as Sole Bookrunner and Sole Lead Arranger TABLE OF CONTENTS Page ARTICLE I Defin |
|
| October 27, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ViroPharma, Inc. - Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-21699 VIROP |
|
| October 27, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody Jr. Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (for media) Associate Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports Third Quarter 2011 Financial Results - Quarter Highlighted by Reco |
|
| October 27, 2011 |
Exclusive License Agreement Exhibit 10.2 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (t |
|
| October 27, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 27, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizat |
|
| September 30, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Jr. Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (for media) Associate Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA LICENSES RIGHTS FROM INTELLECT NEUROSCIENCES FOR PRODUCT CANDIDATE FOR FRIEDREICH?S ATAXIA Exton, PA, September 30, 2011 ? ViroPharma Incorporated (NASDAQ: VPHM) today anno |
|
| September 30, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 29, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organiz |
|
| September 15, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 14, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organiz |
|
| September 15, 2011 |
VIROPHARMA ANNOUNCES ADDITIONAL SECURITIES REPURCHASE PROGRAM Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 VIROPHARMA ANNOUNCES ADDITIONAL SECURITIES REPURCHASE PROGRAM Exton, PA, September 15, 2011 ? ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company?s Board of Directors has authorized the use of up to an additional $200 million to repurchase shares of its com |
|
| September 13, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 13, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organiz |
|
| September 13, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Kristina M. Broadbelt (for media) Associate Director, PR & Advocacy Phone (610) 321- 2358 Robert A. Doody Jr. Assistant Director, Investor Relations Phone (610) 321-6290 HALOZYME Contact: Kurt Gustafson Chief Financial Officer Phone (858) 704-8272 VIROPHARMA AND HALOZYME THERAPEUTICS ANNOUNCE INITIATION OF PHASE 2 EVALUATION OF SUBCUTANEOUS DELIVERY O |
|
| September 9, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 9, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or |
|
| September 6, 2011 |
ViroPharma, Inc. - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 6, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction |
|
| September 6, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (Media) Associate Director, PR & Advocacy Phone (610) 321-2358 VIROPHARMA’S BUCCOLAM® (MIDAZOLAM, OROMUCOSAL SOLUTION) GRANTED EUROPEAN MARKETING AUTHORIZATION FOR TREATMENT OF ACUTE SEIZURES - Approval Offers Convenient Alternative to Treat Seizures in C |
|
| July 28, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 28, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organization |
|
| July 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-21699 VIROPHARMA INCORPORATED (Exact Name of |
|
| July 28, 2011 |
Exhibit 10.2 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. SECOND AMENDMENT TO PROJECT AGREEMENT No. 2 BETWEEN VIROPHARMA INCORPORATED AND NORWICH |
|
| July 28, 2011 |
COLLABORATION AND LICENSE AGREEMENT Exhibit 10.1 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as ?***?. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. COLLABORATION AND LICENSE AGREEMENT THIS COLLABORATION AND LICENSE AGREEMENT (this ?Agre |
|
| July 28, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody Jr. Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (for media) Associate Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports Second Quarter 2011 Financial Results - Quarter Highlighted by Rec |
|
| June 24, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 24, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organization |
|
| June 24, 2011 |
Press Release Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (Media) Associate Director, PR & Advocacy Phone (610) 321-2358 VIROPHARMA ANNOUNCES POSITIVE CHMP OPINION FOR BUCCOLAM® (MIDAZOLAM, OROMUCOSAL SOLUTION) IN THE EUROPEAN UNION Exton, PA, June 24, 2011 — ViroPharma Incorporated (Nasdaq: VPHM) |
|
| June 15, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (Media) Associate Director, PR & Advocacy Phone (610) 321-2358 VIROPHARMA?S CINRYZE? (C1 INHIBITOR [HUMAN]) GRANTED EUROPEAN MARKETING AUTHORIZATION FOR HEREDITARY ANGIOEDEMA (HAE) - First and Only Approved Therapy to Meet HAE Patients? Multiple Managemen |
|
| June 15, 2011 |
ViroPharma Incorporated - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 31, 2011 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 25, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organization) |
|
| May 26, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 26, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Orga |
|
| May 24, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 23, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organization) |
|
| May 11, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (Media) Associate Director, PR & Advocacy Phone (610) 321-2358 VIROPHARMA AND HALOZYME ANNOUNCE COLLABORATION FOR COMBINATION OF RECOMBINANT HUMAN HYALURONIDASE ENZYME (rHuPH20) TECHNOLOGY WITH C1 ESTERASE INHIBITOR - Initial Clinical Focus in Hereditary |
|
| May 11, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 10, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organization) |
|
| April 28, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 28, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| April 28, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody Jr. Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (for media) Associate Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports First Quarter 2011 Financial Results - Company Sets New High in Qu |
|
| April 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 15, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdiction of Incorporation or Organization) 0-021699 (Commiss |
|
| April 14, 2011 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 18, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 18, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Or |
|
| March 18, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (Media) Associate Director, PR & Advocacy Phone (610) 321-2358 VIROPHARMA ANNOUNCES POSITIVE CHMP OPINION FOR CINRYZE® (C1 INHIBITOR [HUMAN]) IN EUROPEAN UNION - Approval Recommended for Three Indications: Routine Prevention, Pre-Procedure Prevention, and |
|
| March 9, 2011 |
Viropharma Incorporated - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2011 |
VIROPHARMA ANNOUNCES SECURITIES REPURCHASE PROGRAM Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Robert A. Doody Assistant Director, Investor Relations Phone (610) 321-6290 VIROPHARMA ANNOUNCES SECURITIES REPURCHASE PROGRAM Exton, PA, March 9, 2011 ? ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company?s Board of Directors has authorized the use of up to $150 million to repurchase shares of its common stock and/or its 2% Senior |
|
| February 24, 2011 |
Exhibit 10.52 VIROPHARMA INCORPORATED AMENDED AND RESTATED 2005 EQUITY INCENTIVE PLAN RESTRICTED SHARE UNIT SUMMARY OF GRANT ViroPharma Incorporated, a Delaware corporation (the ?Company?), pursuant to its Amended and Restated 2005 Equity Incentive Plan, as amended (the ?Plan?), hereby grants to the individual listed below (the ?Participant?), this Restricted Share Unit Award representing the numb |
|
| February 24, 2011 |
Exhibit 21 SUBSIDIARIES OF THE COMPANY Entity Name of State/Country of Incorporation ViroPharma Biologics, Inc. Delaware VCO Incorporated Delaware VPDE Incorporated Delaware VPINT, Inc. Delaware ViroPharma Limited United Kingdom ViroPharma SPRL Belgium ViroPharma SAS France ViroPharma GmbH Germany ViroPharma LLC Switzerland Auralis Limited United Kingdom |
|
| February 24, 2011 |
ViroPharma Incorporated - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 24, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Viropharma Incorporated - Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 24, 2011 |
Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Charles A. Rowland, Jr. Vice President, Chief Financial Officer Phone (610) 321-6223 Robert A. Doody Jr. Assistant Director, Investor Relations Phone (610) 321-6290 Kristina M. Broadbelt (for media) Associate Director, PR & Advocacy Phone (610) 321- 2358 VIROPHARMA Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results - Company Achi |
|
| February 24, 2011 |
ViroPharma Incorporated Board Compensation Policy Exhibit 10.10 ViroPharma Incorporated Board Compensation Policy Members of the Board of Directors of ViroPharma Incorporated (the “Board”) that are non-executive officers of ViroPharma Incorporated (the “Company”), and directors that are not affiliated with a person or entity that has been granted a contractual right to appoint a director to the Board (“Eligible Directors”), shall receive compensa |
|
| February 24, 2011 |
Exhibit 10.51 *** INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED. ViroPharma Incorporated, 730 Stockton Drive, Exton, PA 19341, USA December 14, 2010 Amended and Restated Bulk Materia |
|
| February 24, 2011 |
Second Amended and Restated Bulk Material Supply Agreement Exhibit 10.50 *** INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED. Second Amended and Restated Bulk Material Supply Agreement Parties ViroPharma Incorporated, a Delaware corporation, w |
|
| February 14, 2011 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ViroPharma Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 928241108 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIROPHARMA INC (Name of Issuer) Common Stock (Title of Class of Securities) 928241108 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 10, 2011 |
VIROPHARMA PROVIDES 2011 OUTLOOK Press release Exhibit 99.1 VIROPHARMA INCORPORATED Contacts: Kristina M. Broadbelt (Media) Assistant Director, PR & Advocacy Phone (610) 321-2358 Robert A. Doody Jr. (Investors) Assistant Director, Investor Relations Phone (610) 321-6290 VIROPHARMA PROVIDES 2011 OUTLOOK Exton, PA, January 10, 2011 — ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief exe |
|
| January 10, 2011 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 10, 2011 VIROPHARMA INCORPORATED (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-021699 23-2789550 (State or Other Jurisdiction of Incorporation or Organizat |
